Anúncio
Anúncio

ELVN

ELVN logo

Enliven Therapeutics, Inc. Common Stock

15.47
USD
Patrocinado
+0.33
+2.21%
07 de jan., 16:00 UTC -5
Encerrado
exchange

Pré-Mercado

15.48

+0.01
+0.10%

Relatórios de Lucros ELVN

Rácio de surpresa positiva

ELVN separação 16 de 22 últimas estimativas.

73%

Próximo Relatório

Data do Próximo Relatório
11 de mar. de 2026
Estimate for Q4 25 (Revenue/ EPS)
$8.50K
/
-$0.38
Mudanças implicadas de Q3 25 (Revenue/ EPS)
--
/
+18.75%
Mudanças implicadas de Q4 24 (Revenue/ EPS)
--
/
-17.39%

Enliven Therapeutics, Inc. Common Stock earnings per share and revenue

On 12 de nov. de 2025, ELVN reported earnings of -0.32 USD per share (EPS) for Q3 25, beating the estimate of -0.44 USD, resulting in a 27.67% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -0.15% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 12 analistas forecast an EPS of -0.38 USD, with revenue projected to reach 8.50 mil USD, implying an aumentar of 18.75% EPS, and -- of --% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Citius Pharmaceuticals Inc. Common
Report Date
26 de dez. de 2025 Para Q4 25
Estimativa
-$0.49
Real
-
Surpresa
-
FAQ
For Q3 2025, Enliven Therapeutics, Inc. Common Stock reported EPS of -$0.32, beating estimates by 27.67%, and revenue of $0.00, 0% as expectations.
The stock price moved down -0.15%, changed from $20.30 before the earnings release to $20.27 the day after.
The next earning report is scheduled for 11 de mar. de 2026.
Based on 12 analistas, Enliven Therapeutics, Inc. Common Stock is expected to report EPS of -$0.38 and revenue of $8.50K for Q4 2025.
Verificar FXEmpire's Earnings Calendar for today's list of reporting companies.
Anúncio